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Purpose: Since its discovery in December 2019, the novel coronavirus SARS-CoV-2 has spread globally, causing the current 
COVID-19 (coronavirus disease-19) pandemic. As there is an increase of infections in the male population, concerns have 
emerged about the potential impact of COVID-19 on male reproductive organs and male fertility. Therefore, this study sys-
tematically investigates the current evidence of SARS-CoV-2 impact on male reproduction and pregnancy outcomes, discuss-
ing them in light of the evidence published on other coronaviruses. 
Materials and Methods: Literature search was carried out according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines. A total of 24 original articles were included for the analysis, investigating the effects 
of the infection on semen parameters, male reproductive hormones, and pregnancy outcomes. Further, a Strengths-Weak-
nesses-Opportunities-Threats (SWOT) analysis was conducted based on the available evidence linking the virus with male 
reproduction and conception.
Results: Although there is limited data, viral mRNA has been identified in semen of infected men, with some evidence of 
altered seminal parameters. Low testosterone and dihydrotestosterone with raised luteinizing hormone has been reported as 
well as preterm delivery in pregnant women; however, data regarding vertical transmission remains contradictory and incon-
clusive. 
Conclusions: The recent literature provides evidence that male gonads may be potentially vulnerable to SARS-CoV-2 infec-
tion, recommending caution to pregnant women and couples planning natural pregnancy or assisted reproduction.
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INTRODUCTION
Coronaviruses (CoVs) belong to the family of Coro-
naviridiae, named based on the presence of antigens 
in their membrane which give them the characteristic 
“crown-like” appearance in ultramicrographs (from 
the Latin corona [crown]). Since the first identifica-
tion in 1965 [1], several CoVs have been identified in 
animals and humans [2-5] and are currently classified 
into 46 different species [6]. Although some CoVs can 
cause minor flu-like symptomatology in humans (i.e., 
human CoVs 229E and OC43) [7], others, such as the 
severe acute respiratory syndrome (SARS)-CoV-1 and 
Middle Eastern Respiratory syndrome (MERS)-CoV, 
have received significant attention due to their high 
rate of infections and mortality [8]. On the basis of 
data reported by the Centers for Disease Control and 
Prevention (CDC), both SARS-CoV-1 and MERS-CoV 
infections can cause fever and cough, and be associated 
with the development of other severe complications, 
such as diarrhea and pneumonia (https://www.cdc.gov/
sars/about/fs-sars.html; https://www.cdc.gov/coronavi-
rus/mers/about/symptoms.html).
A novel CoV emerged in December 2019, termed 
SARS-CoV-2 by the International Virus Taxonomy 
Committee (https://talk.ictvonline.org/) [9] due to its ge-
netic similarities to the SARS-CoV-1 virus (79.5%) [10]. 
The infection has been termed “COVID-19” (coronavirus 
disease-19), as this is a CoV-related disease that was 
discovered originally in 2019. This virus has exceeded 
other CoVs in infection rate, and has spread rapidly 
from its origins in Wuhan, China [11,12]. SARS-CoV-2 
has been identified as a member of the β-coronavirus 
subgroup, with a positive-sense single strand RNA, lo-
cated within a nucleocapsid contained in an envelope 
[11,13,14]. The viral structure includes characteristic 
spike (S) proteins that are projected from the virion 
surface and assist viral cell entry, membrane (M) and 
envelope (E) proteins that assist in viral assembly, and 
the N protein which forms the nucleocapsid [11]. The 
S protein mediates viral transfer into host cells, and 
is composed of two unique subunits, S1 and S2. The 
S1 domain functions in virus binding to the host cell 
membrane, while the S2 domain is responsible for the 
fusion of virus to host cell membranes to facilitate the 
viral genome in entering the host cell. Viral S proteins 
undergo proteolytic priming by the transmembrane 
protease, serine 2 (TMPRSS2) [15]. Many receptors on 
the human cell membrane are identified which are 
involved in S1 protein binding to host cells [11]. The 
SARS-CoV-2 may gain access to host cells through the 
angiotensin-converting enzyme 2 (ACE2) receptor, with 
a higher affinity than reported in SARS-CoV-1 [11,16] 
(Fig. 1). These receptors are widely expressed in the 
lungs (particularly type II pneumocytes and macro-
phages), cardiovascular system, gastrointestinal system, 
kidneys, neurological tissues, and the testes [10,17,18]. 
Here, the viruses replicate within the cells, releasing 
mature virions, which in turn infect new target cells 
[19]. 
Evidence strongly suggests human-to-human trans-
mission through droplets spread [10,20]. The median 
incubation period is estimated to be 5 days following 
exposure, with a reported range of 2–14 days [21,22]. 
The typically described presentation includes pyrexia 
(88%), dry cough (67%), fatigue (38.1%), productive 
cough (33%), dyspnea (18%), pharyngitis (13%), and 
headache (13%) [12]. The more severe cases develop 
pneumonia [10,12]. Complications include acute respira-
tory distress syndrome, shock, liver dysfunction and 
secondary infection. Gastrointestinal symptoms, such 
as abdominal pain, poor appetite, nausea, vomiting, and 
diarrhoea have also been reported [10,23]. Laboratory 
results suggest leukopenia and lymphocytopenia [10]. 









Fig. 1. Cellular entry mechanism. Severe acute respiratory syndrome-
coronaviruse-2 (SARS-CoV-2) infection is mediated by the binding 
between viral spike proteins and angiotensin I converting enzyme 
2 (ACE2) cellular receptor, and the further proteolytic cleavage and 




which is significantly lower than MERS, SARS-CoV-2 
is expected to result in many more deaths due to its 
widespread infections [12]. Currently, diagnosis is based 
on nucleic acid identification in oropharyngeal swabs 
through real-time polymerase chain reaction and next-
generation sequencing [10]. Risk factors for hospitaliza-
tion includes those who are age older than 60 years, 
male sex, obesity, smokers, and underlying conditions 
including hypertension, cardiovascular disease, diabe-
tes, and chronic respiratory diseases [24]. 
There has been a significant rise in publications and 
pre-publications on SARS-CoV-2 and COVID-19 with 
more than 6 million cases worldwide until June 2020. 
Male patients have a higher risk for infection and 
symptoms compared to women in both SARS and CO-
VID-19 [14,25,26]. However, any adverse effects on the 
male reproductive system have been generally under-
investigated. This is relevant, as SARS-CoV-1 virus has 
reportedly been able to impact the testicles and cause 
viral orchitis [27]. On February 20, 2020, the American 
Society for Reproductive Medicine (ASRM) and the 
Society for Assisted Reproductive Technology (SART) 
recommended for couples to avoid or postpone preg-
nancy and assisted reproductive techniques (ART) in 




ingthe-novel-coronavirus-covid-19/). In the case of other 
infectious diseases, such as human immunodeficiency 
virus (HIV), sperm processing techniques including 
washing steps were reported to significantly reduce 
seminal viral loads and the probability of infection [28]. 
However, there is a lack of evidence regarding the pos-
sible adverse effect of SARS-CoV-2 on the reproductive 
system [29]. 
Therefore, the aim of this study is to systematically 
review the emerging data on SARS-CoV-2 in order 
to understand its known and potential impact on the 
male reproductive system and male fertility.
MATERIALS AND METHODS 
1. Review criteria: search strategy
The literature search was performed according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines. The following 
keyword string was used to retrieve publications from 
the PubMed and Google Scholar databases: (“severe 
acute respiratory syndrome–coronavirus 2” OR “severe 
acute respiratory syndrome coronavirus 2” OR “CO-
VID-19” OR “SARS-CoV-2” OR “2019-nCoV” OR “SARS 
CoV2” OR “SARS CoV 2”) AND (“semen” OR “sperm*” 
OR “seminal” OR “testes” OR “testicular” OR “male fer-
til*” OR “male infertil*” OR “epididymis” OR “prostate” 
OR “testosterone” OR “LH” OR “FSH” OR “pregnancy” 
OR “ART” OR “assisted reproduc*” OR “IVF” OR “in 
vitro fertilization” OR “ICSI” OR “intracytoplasmic 
sperm injection” OR “cryopreservation”). 
The literature search was conducted independently 
by two authors (RF and KL) via manual screening of 
the titles and abstracts of retrieved articles. Original 
studies conducted in humans evaluating the impact 
of SARS-CoV-2 infection on semen quality, reproduc-
tive hormones and pregnancy outcomes were included 
in this systematic review without any restriction on 
publication language. Reviews, meta-analysis and other 
type of publications not reporting original clinical data 
were excluded. Also, studies conducted in vitro or in 
animal models and studies investigating the impact 
of other CoVs on reproductive system were excluded. 
After the preliminary screening, the full text of the se-
lected articles was checked for eligibility.
RESULTS
1. Search strategy results
A total number of  1,171 articles were identified 
through the application of the keyword search strat-
egy. Duplicates (n=579) and not relevant articles (n=459) 
were excluded by screening the title and abstract (Fig. 
2). Additionally, 109 articles were excluded after the 
full-text was screened for eligibility. After screening, 
24 articles were considered eligible for inclusion in 
this study, including studies investigating the impact 
of SARS-CoV-2 infections on semen parameters (n=6), 
male reproductive hormones (n=3), and pregnancy out-
come (n=15) (Table 1). 
2.  Severe acute respiratory syndrome-
coronaviruse-2 in semen
Six studies investigated semen samples from infected 
patients [30-34]. Five of the 6 studies involving a total 
of 82 patients with active or resolving infection failed 
to detect the presence of SARS-CoV-2 viral RNA in 
any of the semen samples [30-34]. On the other hand, 
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Li et al [35] tested semen samples from 38 patients and 
identified SARS-CoV-2 RNA in the semen of 6 patients 
(15.8%), 4 (66.7%) of whom were in the acute stage of 
infection and 2 (33.3%) were recovering. Furthermore, 
the authors did not find any significant difference in 
clinical characteristics (age, urogenital disease history) 
or disease progression (days since onset, days since 
hospitalization, or days since clinical recovery) between 
patients with negative and positive SARS-CoV-2 infec-
tion [33]. Therefore, the data available on a combined 
number of 120 patients in these 6 studies reveals that 
the virus is identified in the semen of 6 patients (5%) 
with COVID-19 infection [30-34]. 
A single study investigated the impact of SARS-
CoV-2 viral infection on semen analysis results [32]. 
The authors compared conventional semen parameters 
between 20 COVID-19 patients (18 recovered, 2 active) 
and 14 healthy volunteers. Patients were sub-classified 
into mild and moderate groups based on whether hos-
pitalization was required during active infection. Pa-
tients with moderate infection had significantly lower 
sperm concentration (16.2±22.4 ×106/mL), total number 
of sperm per ejaculate (11.9±13.4 ×106), total number 
of motile sperm (4.7±5.5 ×106), and total number of 
progressively motile sperm (2.4±2.7 ×106) compared 
to patients with mild infection (sperm concentration: 
95.9±50.5 ×106/mL; total number of sperm per ejacu-
late: 243.7±140.4 ×106; total number of motile sperm: 
157.1±120.8 ×106; total number of progressively motile 
sperm: 125.3±96.4 ×106) or the control group (sperm con-
centration: 89.5±69.6 ×106/mL; total number of sperm 
per ejaculate: 233.1±234.4 ×106; total number of motile 
sperm: 124.0±124.9 ×106; total number of progressively 
motile sperm: 102.1±102.3 ×106) (p<0.05 for all). 
3. COVID-19 and male reproductive hormones
The impact of SARS-CoV-2 on male reproductive hor-
mones was investigated by three studies. In the first 
study, Ma et al [36] reported the first evidence linking 
SARS-CoV-2 infection with disturbances in male sex 
hormones in a non-peer reviewed study. The authors 
compared sex-related hormones between 81 reproduc-
tive-aged men with SARS-CoV-2 infection and 100 age-
matched healthy men. Although serum testosterone 
was not statistically different between both groups, 
significantly increased serum luteinizing hormone 
(LH) levels (p<0.0001) and decreased testosterone:LH 
(p<0.0001) and follicle stimulating hormone:LH 
(p<0.0001) ratios were observed in recovered patients 
compared to the healthy counterparts [36]. Linear re-
gression analysis showed that the testosterone:LH ratio 
in COVID-19 patients was negatively associated with 
disease severity (p=0.0236), aspartate transaminase 
concentration (p=0.0287), and c-reactive protein (CRP) 
levels (p<0.0001), while a positive association was re-
ported with serum AMH level (p=0.0128) [36].
Fig. 2. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 


































Table 1. Studies included in this systematic review
Number Study Reported outcome
Grade of 
evidencea
Seminal fluid and semen parameters
1 Li et al (2020) [35] 15.8% of cohort tested positive for seminal SARS-CoV-2; 66.7% acute infectious patients 
tested positive; 33.3% recovering patients tested positive.
Level 4
2 Ning et al (2020) [34] All samples were negative for the N gene and ORF1ab gene. Level 3
3 Holtmann et al (2020) [32] No detection of virus RNA in all semen samples;
Moderate infections showed impaired semen parameters.
Level 3
4 Pan et al (2020) [30] No detection of the virus in any semen sample;
Clinical evidence of orchitis at time of COVID-19 diagnosis in 19% of patients;
Single-cell scRNA-seq demonstrates sparse expression of ACE2 and TMPRSS2.
Level 3
5 Paoli et al (2020) [33] No detection of virus RNA in urine or semen. Level 4
6 Song et al (2020) [31] No detection of the virus in any semen sample. Level 4
Male reproductive hormones
7 Rastrelli et al (2020) [37] Low total testosterone levels were observed in the most severe COVID-19 cases. Level 2
8 Ma et al (2020) [36] Significantly increased serum LH levels and decreased testosterone:LH and FSH:LH 
ratios were observed in recovered patients compared to the healthy counterparts.
Level 2
9 Schroeder et al (2020) [38] Most of the men with COVID-19 had low testosterone and dihydrotestosterone levels, 
associated with high levels of inflammatory cytokines, such as IFN-γ and IL-2.
Level 3
Pregnancy outcomes
10 Zhang et al (2020) [50] No significant intraoperative complications in COVID-19 patients; no difference in fetal 
birth weight between COVID-19 patients and controls.
No detection of COVID-19 infection in newborn infants and development of neonatal 
complications.
Level 3
11 Li et al (2020) [53] Significantly higher preterm delivery due to maternal complications in COVID-19 patients.
COVID-19 infection was not detected in newborn infants and none developed neonatal 
complications.
Level 3
12 Liao et al (2020) [51] No difference in maternal (gestational age, postpartum hemorrhage, and perineal 
resection rates) and neonatal outcomes (birth weight and neonatal asphyxia rates) 
reported for COVID-19 patients.
Level 2
13 Futterman et al (2020) [40] 1 patient (22 weeks of gestation) underwent intrauterine fetal demise.
1 patient (29 weeks of gestation) underwent emergency cesarean delivery for non-
reassuring fetal status.
Level 4
14 Sentilhes et al (2020) [39] 3 out of 21 pregnant women underwent preterm deliveries due to maternal respiratory 
complications.
Level 3
15 Knight et al (2020) [41] 5% of the infants were positive for COVID-19 infection. Level 2
16 Cooke et al (2020) [42] No detection of COVID-19 infection in newborn infants. Level 4
17 Govind et al (2020) [43] 1 out of 9 newborns was positive for SARS-CoV-2 RNA. Level 4
18 González Romero et al (2020) [52] No detection of COVID-19 infection in newborn infant. Level 4
19 Yang et al (2020) [46] No differences were reported in maternal status in the prenatal and postpartum period.
No detection of COVID-19 infection in newborn infants.
Level 3
20 Khan et al (2020) [47] No detection of COVID-19 infection in newborn infants. Level 4
21 Khan et al (2020) [48] 5 out of 17 pregnant women showed complications. All of them required caesarean section.
2 out of 17 babies were positive to the SARS-CoV-2 RNA, while 5 out of 17 showed 
neonatal pneumonia.
Level 4
22 Chen et al (2020) [49] No detection of COVID-19 infection in newborn infants. Level 3
23 Liu et al (2020) [44] Successful delivery reported for all pregnant patients, with no neonatal complications. Level 4
24 Liu et al (2020) [45] 5 out of 13 patients required caesarean section due to complications.
No detection of COVID-19 infection in newborn infants.
Level 4
SARS-CoV-2: severe acute respiratory syndrome-coronaviruse-2, ACE2: angiotensin-converting enzyme 2, TMPRSS2: transmembrane protease, 
serine 2, LH: luteinizing hormone, FSH: follicle stimulating hormone, IFN: interferon, IL: interleukin.
aGrade of evidence is evaluated based on Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence (https://www.cebm.net/wp-content/ 
uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf). For more details: https://www.cebm.net/2011/06/explanation-2011-ocebm-levels-evidence/.
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In the second study, Rastrelli et al [37] reported that, 
in COVID-19 recovered patients, total testosterone 
levels were negatively related to CRP levels, with low 
total testosterone levels observed in the most severe 
cases. In the third study, a non-peer reviewed study 
from Germany reported that the majority of men with 
COVID-19 had low testosterone and dihydrotestoster-
one levels [38]. These results suggest that hypogonad-
ism may be considered as a risk factor for COVID-19, 
leading to higher morbidity and mortality.
4. COVID-19 and pregnancy outcomes
The coronavirus epidemic also has implications on 
pregnancy and natural conception. Our literature 
search identified 15 studies including 598 confirmed 
cases of SARS-CoV-2 investigating maternal and neo-
natal consequences of the disease [39-53]. Symptoms of 
COVID-19 were reported by 98.3% of pregnant women, 
with fever (64.2%), cough (56.2%), and dyspnea (34.05%) 
being the most common. Intensive care unit admission 
was required in 8.5% of pregnant women, and maternal 
mortality was identified in 0.8% of the cases. Preterm 
delivery occurred in 33.2% of women, and caesarean 
section was the most common method of delivery, oc-
curring in 88% of cases. Perinatal mortality was 1.5%, 
with 2 intrauterine fetal deaths, 4 still births, and 2 
neonatal deaths reported out of 528 cases. Low birth 
weight was reported in 7.6% of neonates, and 30% re-
quired neonatal intensive care unit (NICU) admission. 
Vertical transmission was reported in 2.3% of cases.
Four case-control studies on pregnant women have 
been published thus far. Zhang et al [50] retrospec-
tively compared sixteen COVID-19-positive with forty-
five COVID-19-negative women. None of  the cases 
progressed to severe pneumonia and both infected and 
controls delivered by caesarean section with no signifi-
cant difference in the gestational age between both 
groups [50]. Additionally, no significant intraoperative 
complications were encountered, and the fetal birth 
weight was not significantly different between both 
groups. Li et al [53] compared sixteen COVID-19 con-
firmed patients with pneumonia to eighteen suspected 
COVID-19 pneumonia patients who were admitted to 
labour. Preterm delivery due to maternal complications 
was reported in 3 patients (18.8%), and was significant-
ly higher than controls (16.7%) [53]. In both studies, CO-
VID-19 infection was not detected in newborn infants 
and none developed neonatal complications. Liao et al 
[51] retrospectively analysed the records of 10 pregnant 
women diagnosed with COVID-19 and compared their 
outcomes with 53 pregnant controls. No significant 
differences in maternal outcomes (gestational age, 
postpartum haemorrhage, and perineal resection rates) 
or neonatal outcomes (birth weight and neonatal as-
phyxia rates) were reported between the two groups 
[51]. Finally, Yang et al [46] retrospectively reviewed 
the charts of 55 pregnant women who were suspected 
to have COVID-19 (13 confirmed cases and 42 controls). 
No significant differences were reported in peripartum 
complications, mode of delivery, or neonatal outcomes 
between the two groups [46].
DISCUSSION
1.  Coronaviruses infection and male 
reproduction
Although there is significant individual variation, 
some viruses have the potential for ongoing viral shed-
ding though seminal fluid. Ebola viral RNA may be 
detected in seminal fluid for more than 13 months fol-
lowing infection [54]. Animal models also suggest pro-
longed shedding of the Zika virus in seminal fluid [55]. 
Based on the reported evidence, it is still unclear if the 
SARS-CoV-2 virus originates from testis, epididymis or 
accessory sex glands or even the renal system. 
Other CoVs, such as SARS-1-CoV, have been associ-
ated with the development of orchitis. Xu et al [27] re-
ported pathological testicular changes including germ 
cell damage, thickened basement membrane, and leu-
kocyte infiltration, with few or no spermatozoa in the 
seminiferous tubules of patients who died for SARS. 
Viral orchitis may occur as a complication of a viral in-
fection and is typically due to haematogenous dissemi-
nation through viremia. Mumps is the most common 
viral pathology associated with orchitis, presenting as 
testicular pain, swelling, warmth and erythema of the 
testes in the acute setting [56]. Additional viruses that 
are known to causes orchitis include hepatitis B and C 
viruses, human papilloma virus, herpes simplex virus, 
influenza virus, Epstein–Barr virus, Coxsackie viruses, 
HIV, Zika virus, Ebola virus, Arbovirus, and Marburg 
virus. 
Both spermatogenesis and testosterone production 
may be affected by viral orchitis. Viral infection of 
testicular tissue is associated with perivascular lym-
phocytic infiltration and interstitial edema, which can 
https://doi.org/10.5534/wjmh.200134
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induce hyalinisation of the seminiferous tubules and 
fibrosis and atrophy of the testes [57]. In the acute 
phase of infection, scrotal discomfort and orchidoptosis 
prevail with variable intensity [56]. Fever, a common 
symptom in viral illnesses, is well known to cause tran-
sient impairment of spermatogenesis [58]. Nonetheless, 
the persistent reduction in semen parameters that has 
been reported following post-pubertal mumps orchitis 
is believed to be due to viral induced damage of the 
seminiferous tubules [59]. 
Testosterone has a sex specific protective effect on 
inflammation and vascular aging [60]. Low testosterone 
levels in COVID-19 patients are associated with high 
levels of inflammatory cytokines, such as interferon-γ 
and interleukin-2 [38]. Since hypogonadism is a com-
mon finding in systemic illnesses, it is unknown 
whether low testosterone levels observed in COVID-19 
patients are the cause or the result of severe infection 
[61,62]. Moreover, testosterone has anti-inflammatory 
and immunomodulatory properties as it can regulate 
the differentiation of T-lymphocytes [63]. However, 
contrary to the potentially protective nature of testos-
terone, others have suggested that COVID-19 infection 
may be mediated by testosterone [64]. This is based on 
the fact that TMPRSS2 is activated by androgen recep-
tors and is believed to be an essential protease for viral 
spread and transmission [61]. TMPRSS2 can also cleave 
both ACE2 and viral S protein to facilitate viral entry 
into the cells [65]. Testosterone mediated modulation of 
TMPRSS2 expression is believed to be one of the rea-
sons for male predominance of COVID-19 infections [66]. 
These facts advocate the need for further research in-
vestigating the relationship between testosterone levels 
and COVID-19 infection. 
2.  Coronaviruses infection and pregnancy 
outcomes
While the viruses responsible for SARS and MERS 
had a more limited spread than SARS-CoV-2, their 
impact on overall human health including natural 
conception was more severe. In SARS, pregnant women 
were three times more likely to require mechanical 
ventilation and had a higher incidence of mortality 
than non-pregnant women [67]. Miscarriage was ob-
served in more than half of pregnant women who con-
tracted SARS during their first trimester, and 80% of 
women contracting the disease in the third trimester 
delivered prematurely [68,69]. While there was no evi-
dence of vertical transmission, infants born to SARS-
positive women either developed respiratory distress 
syndrome requiring surfactant or had fetal growth 
restriction [68,69]. 
MERS had a similar impact on natural conception as 
a high incidence of NICU admissions (64%) and overall 
mortality (23%) were observed in infected pregnant 
women [70-74]. A total of 9 cases were reported in the 
literature to have contracted MERS after their first 
trimester, showing substantial complications. Compli-
cations were reported in 6 patients: One patient had a 
miscarriage at 20-weeks’ gestation [75], one developed 
pre-eclampsia and had an intrauterine fetal demise, 
one with pre-existing respiratory issues died from the 
disease, and three delivered prematurely [71]. 
3.  Angiotensin-converting enzyme 2 in male 
reproductive tissues
There is limited evidence regarding the effects of 
SARS-CoV-2 on male reproduction [76]. However, bio-
informatic analysis suggests that this virus may po-
tentially infect reproductive tissues. The Human Pro-
tein Atlas database (https://www.ebi.ac.uk/gxa/home) 
reports the expression of ACE2 receptors in both male 
and female reproductive organs [77-79]. This receptor 
has a significant role in sperm function [80] and in 
oocyte fertilization [81]. Increased ACE2 receptor ex-
pression is reported in testicular tissues, particularly 
in spermatogonia, Sertoli and Leydig cells, as well as 
in prostate epithelial cell clusters, fibroblasts and peri-
cytes (Fig. 3). There is a lower expression of ACE2 in 







Fig. 3. The putative mechanisms by which severe acute respiratory 
syndrome-coronaviruse-2 (SARS-CoV-2) might affect spermatogen-
esis are here summarized. ACE2: angiotensin-converting enzyme 2.
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spermatocytes, late spermatocytes, spermatids and oth-
er somatic cells [82,83]. Furthermore, a high expression 
of the protease TMPRSS2 is also reported in germ and 
somatic cells. Androgens are the only identified tran-
scriptional regulator for TMPRSS2 gene expression [84], 
due to the presence of a 15 base pair (bp) androgen re-
sponse element in the TMPRSS2 gene. In vitro and in 
vivo studies confirm that castration leads to decreased 
expression of both ACE2 and TMPRSS2, while andro-
gen supplementation therapy can reverse this decrease 
[83]. However, TMPRSS2 and ACE2 proteins show a 
different expression profile, with the former highly ex-
pressed in Sertoli cells and the latter in spermatogonial 
stem cells. This seems to exclude a possible viral infec-
tion of testicular tissue, however an interplay between 
somatic and spermatogenic cells might provide the 
virus the necessary molecular components to infect the 
cells. 
Wang and Xu [85] reported an enrichment of Gene 
Ontology (GO) terms related to viral reproduction and 
transmission in ACE2-positive cells and reduced GO 
terms related to male reproduction, suggesting a pos-
sible disruption of spermatogenesis in case of infection. 
Moreover, the enrichment of GO terms in ACE2-pos-
itive cells related to the organization of cell junctions 
suggest a viral transmission through the cellular junc-
tions while the reduced GO terms related to mitochon-
dria and reproduction suggest a reduced capability of 
Sertoli and Leydig cells to support spermatogenesis [83]. 
4.  Strengths-weaknesses-opportunities-
threats (SWOT) analysis
A SWOT analysis has been conducted to assess the 
available evidence linking the virus with male repro-
duction and conception (Fig. 4).
1) Strengths
The available evidence demonstrates an impact of 
COVID19 infection on male and female reproduction 
(Table 1). Histopathologic studies identifying the ex-
pression of ACE2 in testicular tissues have revealed 
that the SARS-CoV-2 virus can gain access to repro-
ductive tissues. Viral shedding in the seminal fluid 
has been reported in men with active disease or those 
recovering from infection. Others have linked SARS-
CoV-2 infection with disturbances in male sex hor-
mones [37], or have even identified hypogonadism as 
a risk factor for worse COVID-19 outcomes [38]. With 
regards to the impact of SARS-CoV-2 on pregnancy 
outcomes, the available evidence reveals less severe 
consequences compared to those witnessed with SARS 
and MERS. 
2) Weaknesses
This pandemic has significantly affected the health 
care systems of various countries around the globe. To 
Strengths Weaknesses
Threats Opportunities
SARS-CoV-2 virus has been
detected in the semen of men
with active infection or in recovery
Hypogonadism may worsen
SARS-CoV-2 severity
SARS-CoV-2 infection effect on
pregnancy outcome is less severe than
SARS or MERS
Most of studies examining the link
between SARS-CoV-2 and male
reproduction were observational,
under sized, and reporting rather
heterogenous outcomes
SARS-CoV-2 effect on early stages
of conception is unknown
A weak level of evidence may
jeopardize the recommendations
set forth for resumption of
reproductive services
More research should be
conducted to clarify the effect
of SARS-CoV-2 on male and
female reproduction
S W O T
Fig. 4. Strengths-Weaknesses-Opportu-
nities-Threats (SWOT) analysis has been 
conducted to define if there is an impact 
of the virus in the male reproduction. 
SARS-CoV-2: severe acute respiratory 




facilitate the dissemination of findings on multiple as-
pects of this novel infection, almost all scientific jour-
nals implemented fast tracking for COVID-19 related 
publications. While such action is needed, the less dili-
gent peer-review process may certainly affect the qual-
ity of the published literature. Moreover, few number 
of studies included are not peer-reviewed.
Most of the published studies examining the link 
between SARS-CoV-2 and male reproduction were ob-
servational, under-sized, and reporting rather heterog-
enous outcomes. This may certainly affect the accuracy 
of the available evidence and, to a variable extent, 
might influence the creation of optimum recommenda-
tions and guidelines. Furthermore, conception studies 
were mostly conducted in the third trimester or in 
women at the time of delivery and little is known on 
the consequences of this infection on the earlier stages 
of pregnancy at this time.
3) Opportunities
Reproduction is an essential field of medicine and 
many couples are eagerly waiting to resume treatment. 
Further research is needed to accurately assess the ef-
fect of SARS-CoV-2 on the testis, semen parameters, 
reproductive hormones, and pregnancy outcomes to 
help determine when and how couples should begin re-
productive treatments again.
4) Threats
Taking into consideration that this pandemic will 
most likely persist for several years, efforts have been 
made to propose new standards to healthcare practices. 
Establishing recommendations to resume healthcare 
services (and reproductive services in particular) on the 
basis of feeble evidence could be considered a potential 
threat, as this may place both patients and healthcare 
workers at risk of infection or unwanted complications.
5.  Assisted reproductive technique practice 
in COVID-19 pandemic
No research has been conducted to study the impact 
of any of the CoVs on the outcome of ART. The limited 
research examining the effect of COVID-19 infection 
on pregnancy outcomes coupled with previous experi-
ences with other CoVs, led international societies to 
publish recommendations regarding the practice of 
ART during this pandemic. On March 17th, 2020, the 
ASRM published their recommendations for fertility 
related therapies during the COVID-19 pandemic [86]. 
The ASRM advised physicians to “1) Suspend initiation 
of new treatment cycles, including ovulation induction, 
intrauterine inseminations (IUIs), in vitro fertilization 
(IVF) including retrievals and frozen embryo trans-
fers, as well as non-urgent gamete cryopreservation. 
2) Strongly consider cancellation of all embryo trans-
fers whether fresh or frozen. 3) Continue to care for 
patients who are currently “in-cycle” or who require 
urgent stimulation and cryopreservation. 4) Suspend 
elective surgeries and non-urgent diagnostic proce-
dures. 5) Minimize in-person interactions and increase 
utilization of telehealth”.
These recommendations have been updated five 
times since the initial statement and the most recent 
update was published on June 8, 2020 [87]. In their 
third update, the ASRM recognized that the COVID-19 
pandemic has become a reality that needs to be man-
aged for a prolonged period of time [88]. Since fertility 
care is an essential health service, the committee pro-
posed measures to resume patient care. After appropri-
ate risk assessment and mitigation, fertility related 
therapies can be resumed provided that the following 
measures are applied: social distancing, continued use 
of telehealth to minimize the number of in-person con-
sults and to conduct patient counselling and consent-
ing, minimization of the number of in-cycle monitoring 
visits, performing serologic testing for SARS CoV2 
infection on all patients opting for surgery and the 
application of enhanced or expanded precautions for 
infection control. 
The European Society of Human Reproduction and 
Embryology (ESHRE) has recognized that since only 
few cases of COVID-19 infection during pregnancy 
have been reported, caution is advised with regards 
to the interpretation of its potential effects, especially 
since no information is available during the initial 
stages of pregnancy [89]. A joint statement by the ES-
HRE, ASRM, and the International Federation of Fer-
tility Societies was published on May 29th, 2020 urging 
fertility centers to monitor local conditions, including 
governmental regulations and availability of resources 
[90]. Prioritized care strategy may be offered provided 
that risk assessment and mitigation strategies have 
been implemented to maximize the safety of patients 
and staff. 
The detection of the SARS-CoV-2 virus in semen 
samples of infected men, even while recovering [33], 
Mohammad Ali Khalili, et al: Male Fertility and COVID-19 Pandemic
515www.wjmh.org
represents a major risk for cryopreservation. It is well 
known that most viruses can withstand ultra-low 
temperatures especially when stored in proteinaceous 
media [91]. In one study, the influenza virus remained 
infectious after 40 years of  cryopreservation [92]. 
These facts necessitate not only the testing for SARS-
CoV-2 virus in semen samples of patients opting for 
cryopreservation, but also the strict implementation 
of laboratory safety procedures such as using closed 
system vitrification with sterile liquid nitrogen or 
washing and storage in separate cryo-containers [93]. 
In addition, a recent recommendation from fertility 
specialists identified patients who might have a transi-
tory “fertility window” and who should be prioritized 
for cryopreservation [94]. This list includes patients 
with advanced paternal age, those planning to receive 
gonadotoxic therapies (cancer, inflammatory or auto-
immune systemic disorders), azoospermic men who re-
sponded to medical treatment and patients with cryp-
tozoospermia. 
6. Future directions and recommendations
In the reproductive field, treatments such as cryo-
preservation or ART procedures may be considered es-
sential services as well as time-sensitive in case of spe-
cific clinical conditions or advanced female age. As the 
main goals are to guarantee the medical services and, 
at the same time, the safety of patients and staff, ART 
centers have been recommended to reconsider their 
procedures during the early months of the COVID-19 
outbreak. While the first reaction to the pandemic has 
been to interrupt or postpone any treatment, a cau-
tious reopening has progressively begun. Nevertheless, 
further research regarding the mechanisms of the vi-
ral infection is highly warranted. The above evidence 
as well as the previously described reports of ACE2 
expression in the male genital tract suggest that extra 
precautions should be taken for COVID-19 patients 
in order to prevent viral transmission during sexual 
activity and for handling their semen specimens dur-
ing cryopreservation and ART procedures. Moreover, 
the impact of a SARS-CoV-2 infection on reproductive 
outcomes must be further investigated (Fig. 5). Accord-
ingly, larger studies need to be conducted by includ-
ing SARS-CoV-2 positive or recovered male subjects of 
reproductive age. Finally, as the number of pediatric 
patients might be underestimated, longitudinal studies 
are required to assess the long-term impact of SARS-
CoV-2 infection on testicular function and spermato-
genesis in these patients, who may experience potential 
testicular damage and infertility at a later stage.
CONCLUSIONS
The evidence regarding a putative impact of SARS-
CoV-2 infection on male reproduction, as well as the 
potential of SARS-CoV-2 viral transmission though 
seminal fluids, remains inconclusive. However, studies 
conducted on other CoVs suggest potential testicular 
damage and subsequent infertility mediated via direct 
viral invasion or secondary immunological or inflam-
matory response that may negatively affect fertility in 
adults and future reproductive outcomes in pediatric 
patients. Currently, extra precautions are strongly rec-
ommended for natural or ART-related conception, as 
clear evidence regarding the impact of the SARS-CoV-2 
and the possible complications of COVID-19 on repro-
ductive outcomes require needs additional investiga-
tion. 
Key points
1) Male patients are reportedly slightly more affected 
than women by both SARS-CoV-1 and SARS-CoV-2 in-
fections.
Fig. 5. Hypothesis and evidence regarding the possible severe acute respiratory syndrome-coronaviruse-2 (SARS-CoV-2) sexual transmission, as 
well as its impact on natural pregnancy, assisted reproduction and cryopreservation are summarized. ART: assisted reproductive technique.
Sexual transmission Natural pregnancy Assisted reproduction Cryopreservation
Detection of SARS-CoV-2
virus in semen samples from
5% of men with active disease
or in convalescence may




The impact of SARS-CoV-2
on pregnancy appears to be
less severe than other
coronaviruses.
Preterm delivery and low fetal
birth weight are among the most
common implications of
SARS-CoV-2.
ART during the SARS-CoV-2
pandemic may be conducted
after incorporating risk
assessment and mitigation
strategies and when measures
to maximize the safety of
patients and staff have been
employed.
The SARS-CoV-2 may present








2) Although the mechanism by which SARS-CoV-2 
can gain entry in the cell has been explained, there 
remains a lack of evidence to support a significant sus-
ceptibility of the male reproductive tract.
3) In 5 out of 6 studies, viral mRNA was not detected 
in seminal fluids of COVID-19 patients, so the potential 
sexual transmission of SARS-CoV-2 is likely low but 
requires further investigation.
4) Studies reporting the influence of COVID-19 infec-
tion on testosterone are contradictory, although this 
hormone is generally reported to be lower in COVID-19 
patients.
5) Preliminary studies reported that COVID-19 may 
increase the risk of preterm delivery in pregnant wom-
en while reports about vertical transmission are still 
contradictory.
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